129 related articles for article (PubMed ID: 38049963)
1. Novel Biodistribution of PSMA Radiotracer in the Uvula of Patients Undergoing PSMA PET/CT.
Philbrook P; Casano KR; Lee DJ
Clin Nucl Med; 2024 Feb; 49(2):e80-e81. PubMed ID: 38049963
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Lys-urea-Aad, Lys-urea-Cmc and Lys-urea-Cms as potential pharmacophores for the design of PSMA-targeted radioligands to reduce off-target uptake in kidneys and salivary glands.
Kuo HT; Zhang Z; Zhang C; Merkens H; Tan R; Wong AAWL; Uribe CF; Bénard F; Lin KS
Theranostics; 2023; 13(13):4559-4573. PubMed ID: 37649602
[TBL] [Abstract][Full Text] [Related]
4. The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions.
Afshar-Oromieh A; Hetzheim H; Kratochwil C; Benesova M; Eder M; Neels OC; Eisenhut M; Kübler W; Holland-Letz T; Giesel FL; Mier W; Kopka K; Haberkorn U
J Nucl Med; 2015 Nov; 56(11):1697-705. PubMed ID: 26294298
[TBL] [Abstract][Full Text] [Related]
5. Biodistribution of [(68)Ga]PSMA-HBED-CC in Patients with Prostate Cancer: Characterization of Uptake in Normal Organs and Tumour Lesions.
Prasad V; Steffen IG; Diederichs G; Makowski MR; Wust P; Brenner W
Mol Imaging Biol; 2016 Jun; 18(3):428-36. PubMed ID: 27038316
[TBL] [Abstract][Full Text] [Related]
6. Biodistribution and radiation dosimetry of [
Hohberg M; Kobe C; Krapf P; Täger P; Hammes J; Dietlein F; Zlatopolskiy BD; Endepols H; Wild M; Neubauer S; Heidenreich A; Neumaier B; Drzezga A; Dietlein M
EJNMMI Res; 2019 Jul; 9(1):66. PubMed ID: 31346821
[TBL] [Abstract][Full Text] [Related]
7. Normal distribution pattern and physiological variants of 68Ga-PSMA-11 PET/CT imaging.
Demirci E; Sahin OE; Ocak M; Akovali B; Nematyazar J; Kabasakal L
Nucl Med Commun; 2016 Nov; 37(11):1169-79. PubMed ID: 27333090
[TBL] [Abstract][Full Text] [Related]
8. What a difference a methylene makes: replacing Glu with Asp or Aad in the Lys-urea-Glu pharmacophore of PSMA-targeting radioligands to reduce kidney and salivary gland uptake.
Kuo HT; Lin KS; Zhang Z; Zhang C; Merkens H; Tan R; Roxin A; Uribe CF; Bénard F
Theranostics; 2022; 12(14):6179-6188. PubMed ID: 36168623
[TBL] [Abstract][Full Text] [Related]
9. PSMA PET/CT Identifies Intrapatient Variation in Salivary Gland Toxicity From Iodine-131 Therapy.
Mohan V; Vogel WV; Valk GD; de Boer JP; Lam MGEH; de Keizer B
Mol Imaging; 2020; 19():1536012120934992. PubMed ID: 32619138
[TBL] [Abstract][Full Text] [Related]
10. The Impact of Monosodium Glutamate on
Armstrong WR; Gafita A; Zhu S; Thin P; Nguyen K; Alano R; Lira S; Booker K; Gardner L; Grogan T; Elashoff D; Allen-Auerbach M; Dahlbom M; Czernin J; Calais J
J Nucl Med; 2021 Sep; 62(9):1244-1251. PubMed ID: 33509974
[TBL] [Abstract][Full Text] [Related]
11. Correlation of Lesional Uptake Parameters and Ratios with miPSMA Score and Estimating Normal Physiologic Concentration: An Exploratory Analysis in Metastatic Castration-Resistant Prostatic Carcinoma Patients with
Kalshetty A; Menon B; Rakshit S; Bhattacharjee A; Basu S
J Nucl Med Technol; 2021 Sep; 49(3):235-240. PubMed ID: 34244223
[TBL] [Abstract][Full Text] [Related]
12. Early Injection of Furosemide Increases Detection Rate of Local Recurrence in Prostate Cancer Patients with Biochemical Recurrence Referred for
Uprimny C; Bayerschmidt S; Kroiss AS; Fritz J; Nilica B; Svirydenka H; Decristoforo C; von Guggenberg E; Horninger W; Virgolini IJ
J Nucl Med; 2021 Nov; 62(11):1550-1557. PubMed ID: 33712533
[TBL] [Abstract][Full Text] [Related]
13. [
Rosar F; Schaefer-Schuler A; Bartholomä M; Maus S; Petto S; Burgard C; Privé BM; Franssen GM; Derks YHW; Nagarajah J; Khreish F; Ezziddin S
Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4736-4747. PubMed ID: 35930033
[TBL] [Abstract][Full Text] [Related]
14. Physiologic distribution of PSMA-ligand in salivary glands and seromucous glands of the head and neck on PET/CT.
Klein Nulent TJW; Valstar MH; de Keizer B; Willems SM; Smit LA; Al-Mamgani A; Smeele LE; van Es RJJ; de Bree R; Vogel WV
Oral Surg Oral Med Oral Pathol Oral Radiol; 2018 May; 125(5):478-486. PubMed ID: 29523427
[TBL] [Abstract][Full Text] [Related]
15. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions.
Afshar-Oromieh A; Malcher A; Eder M; Eisenhut M; Linhart HG; Hadaschik BA; Holland-Letz T; Giesel FL; Kratochwil C; Haufe S; Haberkorn U; Zechmann CM
Eur J Nucl Med Mol Imaging; 2013 Apr; 40(4):486-95. PubMed ID: 23179945
[TBL] [Abstract][Full Text] [Related]
16. Pilot Comparison of ⁶⁸Ga-RM2 PET and ⁶⁸Ga-PSMA-11 PET in Patients with Biochemically Recurrent Prostate Cancer.
Minamimoto R; Hancock S; Schneider B; Chin FT; Jamali M; Loening A; Vasanawala S; Gambhir SS; Iagaru A
J Nucl Med; 2016 Apr; 57(4):557-62. PubMed ID: 26659347
[TBL] [Abstract][Full Text] [Related]
17. Antihormonal-Treatment Status Affects
Kluge K; Haberl D; Einspieler H; Rasul S; Gutschmayer S; Kenner L; Kramer G; Grubmüller B; Shariat S; Haug A; Hacker M
J Nucl Med; 2023 Nov; 64(11):1730-1736. PubMed ID: 37734840
[TBL] [Abstract][Full Text] [Related]
18.
Grubmüller B; Baum RP; Capasso E; Singh A; Ahmadi Y; Knoll P; Floth A; Righi S; Zandieh S; Meleddu C; Shariat SF; Klingler HC; Mirzaei S
Cancer Biother Radiopharm; 2016 Oct; 31(8):277-286. PubMed ID: 27715146
[TBL] [Abstract][Full Text] [Related]
19. The Effects of Monosodium Glutamate on PSMA Radiotracer Uptake in Men with Recurrent Prostate Cancer: A Prospective, Randomized, Double-Blind, Placebo-Controlled Intraindividual Imaging Study.
Harsini S; Saprunoff H; Alden T; Mohammadi B; Wilson D; Bénard F
J Nucl Med; 2021 Jan; 62(1):81-87. PubMed ID: 32385167
[TBL] [Abstract][Full Text] [Related]
20. PSMA Radioligand Uptake as a Biomarker of Neoangiogenesis in Solid Tumours: Diagnostic or Theragnostic Factor?
Rizzo A; Dall'Armellina S; Pizzuto DA; Perotti G; Zagaria L; Lanni V; Treglia G; Racca M; Annunziata S
Cancers (Basel); 2022 Aug; 14(16):. PubMed ID: 36011032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
